These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

282 related items for PubMed ID: 11138573

  • 1. Acute psychological stress decreases plasma tissue plasminogen activator (tPA) and tissue plasminogen activator/plasminogen activator inhibitor-1 (tPA/PAI-1) complexes in cardiac patients.
    Hevey D, McGee HM, Fitzgerald D, Horgan JH.
    Eur J Appl Physiol; 2000 Nov; 83(4 -5):344-8. PubMed ID: 11138573
    [Abstract] [Full Text] [Related]

  • 2. Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEEP) study.
    Wiman B, Andersson T, Hallqvist J, Reuterwall C, Ahlbom A, deFaire U.
    Arterioscler Thromb Vasc Biol; 2000 Aug; 20(8):2019-23. PubMed ID: 10938026
    [Abstract] [Full Text] [Related]

  • 3. Predictive value of fibrinolytic factors in coronary heart disease.
    Wiman B.
    Scand J Clin Lab Invest Suppl; 1999 Aug; 230():23-31. PubMed ID: 10389198
    [Abstract] [Full Text] [Related]

  • 4. [Dehydroepiandrosterone therapy in men with angiographically verified coronary heart disease: the effects on plasminogen activator inhibitor-1 (PAI-1), tissue plasminogen activator (tPA) and fibrinogen plasma concentrations].
    Rabijewski M, Zgliczyński W.
    Endokrynol Pol; 2007 Aug; 58(3):213-9. PubMed ID: 17940987
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Tissue plasminogen activator and plasminogen activator inhibitor-1 in stroke patients.
    Lindgren A, Lindoff C, Norrving B, Astedt B, Johansson BB.
    Stroke; 1996 Jun; 27(6):1066-71. PubMed ID: 8650716
    [Abstract] [Full Text] [Related]

  • 7. Tissue plasminogen activator, plasminogen activator inhibitor-1, and tissue plasminogen activator/plasminogen activator inhibitor-1 complex as risk factors for the development of a first stroke.
    Johansson L, Jansson JH, Boman K, Nilsson TK, Stegmayr B, Hallmans G.
    Stroke; 2000 Jan; 31(1):26-32. PubMed ID: 10625711
    [Abstract] [Full Text] [Related]

  • 8. Comparative effects of pulsatile and nonpulsatile flow on plasma fibrinolytic balance in pediatric patients undergoing cardiopulmonary bypass.
    Aĝirbaşli MA, Song J, Lei F, Wang S, Kunselman AR, Clark JB, Myers JL, Ündar A.
    Artif Organs; 2014 Jan; 38(1):28-33. PubMed ID: 24237252
    [Abstract] [Full Text] [Related]

  • 9. TM5275 prolongs secreted tissue plasminogen activator retention and enhances fibrinolysis on vascular endothelial cells.
    Yasui H, Suzuki Y, Sano H, Suda T, Chida K, Dan T, Miyata T, Urano T.
    Thromb Res; 2013 Jul; 132(1):100-5. PubMed ID: 23611258
    [Abstract] [Full Text] [Related]

  • 10. Relation of depressive mood to plasminogen activator inhibitor, tissue plasminogen activator, and fibrinogen levels in patients with versus without coronary heart disease.
    Lahlou-Laforet K, Alhenc-Gelas M, Pornin M, Bydlowski S, Seigneur E, Benetos A, Kierzin JM, Scarabin PY, Ducimetiere P, Aiach M, Guize L, Consoli SM.
    Am J Cardiol; 2006 May 01; 97(9):1287-91. PubMed ID: 16635597
    [Abstract] [Full Text] [Related]

  • 11. Long-term treatment with growth hormone decreases plasminogen activator inhibitor-1 and tissue plasminogen activator in growth hormone-deficient adults.
    Johansson JO, Landin K, Johannsson G, Tengborn L, Bengtsson BA.
    Thromb Haemost; 1996 Sep 01; 76(3):422-8. PubMed ID: 8883281
    [Abstract] [Full Text] [Related]

  • 12. Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration.
    Grebenchtchikov N, Maguire TM, Riisbro R, Geurts-Moespot A, O'Donovan N, Schmitt M, McGreal G, McDermott E, O'Higgins N, Brünner N, Sweep CG, Duffy MJ.
    Oncol Rep; 2005 Jul 01; 14(1):235-9. PubMed ID: 15944795
    [Abstract] [Full Text] [Related]

  • 13. Studies on blood coagulation-fibrinolysis system regarding kallikrein-kinin system in the utero-placental circulation during normal pregnancy, labor and puerperium.
    Mutoh S, Kobayashi M, Hirata J, Itoh N, Maki M, Komatsu Y, Yoshida A, Sasa H, Kuroda K, Kikuchi Y.
    Agents Actions Suppl; 1992 Jul 01; 38 ( Pt 2)():320-9. PubMed ID: 1462839
    [Abstract] [Full Text] [Related]

  • 14. Association of plasminogen activator inhibitor-1 and tissue plasminogen activator with type 2 diabetes and metabolic syndrome in Malaysian subjects.
    Al-Hamodi Z, Ismail IS, Saif-Ali R, Ahmed KA, Muniandy S.
    Cardiovasc Diabetol; 2011 Mar 18; 10():23. PubMed ID: 21414238
    [Abstract] [Full Text] [Related]

  • 15. Elevated tissue plasminogen activator in patients with screening-detected abdominal aortic aneurysm.
    Wanhainen A, Nilsson TK, Bergqvist D, Boman K, Björck M.
    J Vasc Surg; 2007 Jun 18; 45(6):1109-13. PubMed ID: 17543671
    [Abstract] [Full Text] [Related]

  • 16. Relationships between euglobulin clot lysis time and the plasma levels of tissue plasminogen activator and plasminogen activator inhibitor 1.
    Urano T, Sakakibara K, Rydzewski A, Urano S, Takada Y, Takada A.
    Thromb Haemost; 1990 Feb 19; 63(1):82-6. PubMed ID: 2111051
    [Abstract] [Full Text] [Related]

  • 17. [A study on the reserve capacity of endothelial tissue plasminogen activator in patients with acute coronary syndrome].
    Yan J, Huang Z, Liu R, Li L, Han C, Yang J.
    Zhonghua Nei Ke Za Zhi; 1999 Dec 19; 38(12):817-20. PubMed ID: 11798724
    [Abstract] [Full Text] [Related]

  • 18. Fibrinolytic proteins and progression of coronary artery disease in relation to gemfibrozil therapy.
    Hamsten A, Syvänne M, Silveira A, Luong LA, Nieminen MS, Humphries S, Frick MH, Taskinen MR.
    Thromb Haemost; 2000 Mar 19; 83(3):397-403. PubMed ID: 10744143
    [Abstract] [Full Text] [Related]

  • 19. The effect of insulin treatment on the balance between tissue plasminogen activator and plasminogen activator inhibitor-1 in type 2 diabetic patients.
    Vukovich T, Proidl S, Knöbl P, Teufelsbauer H, Schnack C, Schernthaner G.
    Thromb Haemost; 1992 Sep 07; 68(3):253-6. PubMed ID: 1440487
    [Abstract] [Full Text] [Related]

  • 20. Relationship of tissue plasminogen activator, plasminogen activator inhibitor-1 and fibrinogen with coronary artery disease in South Indian male subjects.
    Deepa R, Velmurugan K, Saravanan G, Dwarakanath V, Agarwal S, Mohan V.
    J Assoc Physicians India; 2002 Jul 07; 50():901-6. PubMed ID: 12126344
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.